



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 56025

Title: The “six-and-twelve score” for outcome prediction of unresectable HCC treated with TACE. In-depth analysis from a multicenter French cohort

Reviewer’s code: 03261461

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Professor

Reviewer’s Country/Territory: Egypt

Author’s Country/Territory: France

Manuscript submission date: 2020-04-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-04-13 19:16

Reviewer performed review: 2020-04-17 09:53

Review time: 3 Days and 14 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

it is very interesting manuscript , but i have few questions to the authors: 1- p 17 BCLC classification "BCLC stage A was defined as patients having tumor > 2 cm...." i think it is a mistake the correct is lesion < 2cm ,so please correct 2- You have 145 (45%) of the patients BCLC stage A why this patients do TACE ?? no other curative lines line RFA can be offered?? this need clarification as BCLC A can do curative therapy according to guidelines 3- Why you separate Marceillie cohort from the whole cohort i think this added too much tables and nearly the same findings